SCHEDULE 13G/A: BlackRock Discloses 2.1% Passive Stake in Alto Neuroscience
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% passive beneficial ownership stake in Alto Neuroscience Inc.'s common stock.
Summary
- BlackRock, Inc. reported beneficial ownership of 561,363 shares of Alto Neuroscience Inc. common stock.
- This represents 2.1% of the total outstanding common shares of Alto Neuroscience Inc.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment.
- BlackRock holds sole voting power over 557,180 shares and sole dispositive power over 561,363 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Alto Neuroscience Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of passive beneficial ownership by a large institutional investor, BlackRock, Inc., in Alto Neuroscience Inc. It does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or future prospects.
Positives
- BlackRock's continued passive investment indicates a degree of confidence in Alto Neuroscience Inc. as a long-term holding.
- The filing confirms BlackRock's position as a significant institutional shareholder, which can be viewed positively by other investors.
Negatives
- No specific negative information regarding Alto Neuroscience Inc. is disclosed in this ownership filing.
Risks
- The filing itself does not detail specific risks related to Alto Neuroscience Inc.'s operations or financial health.
- As a passive investment, BlackRock does not intend to influence the control of the issuer, which means their stake does not imply active strategic support or intervention.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure Rule | BlackRock, Inc. filed under Rule 13d-1(b), indicating that it is a passive investor holding less than 20% of the class of securities and does not intend to influence or change control of the issuer. | 06/30/2025 | This classification signifies that BlackRock's investment is for ordinary course business purposes, providing transparency without implying active corporate governance engagement or activist intent. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which may offer some stability or validation.
- Management: Confirms a large, passive institutional investor, which typically does not seek to influence management decisions.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement. |
| 07/16/2025 | Date of signature for the Schedule 13G filing. |
Recommendation
holdKeywords
Alto Neuroscience Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.